Cardiff Oncology
CRDF
112 hedge funds and large institutions have $52.1M invested in Cardiff Oncology in 2025 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 32 increasing their positions, 30 reducing their positions, and 20 closing their positions.
192% more call options, than puts
Call options by funds: $2.64M | Put options by funds: $902K
7% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 30
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
2% less funds holding
Funds holding: 114 → 112 (-2)
5.19% less ownership
Funds ownership: 43.08% → 37.89% (-5.2%)
42% less capital invested
Capital invested by funds: $90.3M → $52.1M (-$38.1M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
LCM
Laurion Capital Management
New York
|
+$1.85M |
| 2 |
ACA
Acorn Capital Advisors
New York
|
+$1.53M |
| 3 |
FLPIM
F.L. Putnam Investment Management
Lynnfield,
Massachusetts
|
+$1.5M |
| 4 |
Goldman Sachs
New York
|
+$1.05M |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$577K |
Top Sellers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.48M |
| 2 |
Millennium Management
New York
|
-$3.01M |
| 3 |
Morgan Stanley
New York
|
-$1.34M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.29M |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$1.21M |
CRDF Hedge Fund Activity: Q3 2025 in Review
112 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q3 2025, worth a combined $52.1M — down 42% from $90.3M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CRDF and 19 opened new positions — a net loss of 1 holder — while 30 trimmed existing stakes and 32 added.
The largest buyer was Laurion Capital Management, adding an estimated $1.85M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $4.48M sold.
- 112 institutional investors held Cardiff Oncology (CRDF) as of Q3 2025, down from 114 in Q2 2025.
- Funds reported $52.1M of Cardiff Oncology stock for Q3 2025, down 42% quarter-over-quarter.
- 19 funds opened new Cardiff Oncology positions in Q3 2025 and 20 closed out, a net change of -1 holder.
- The largest Cardiff Oncology buyer in Q3 2025 was Laurion Capital Management, an estimated $1.85M added.
- The largest Cardiff Oncology seller in Q3 2025 was Adage Capital Partners, an estimated $4.48M sold.
Based on aggregated 13F filings for Q3 2025.